Histologic transformation in lung cancer: when one door shuts, another opens

被引：10

作者：

Sato, Yuki ^{[2
]}

Saito, Go ^{[3
]}

Fujimoto, Daichi ^{[1
]}

机构：

[1] Wakayama Med Univ, Internal Med 3, 811-1 Kimiidera, Wakayama 6418509, Japan

[2] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan

[3] Chiba Univ, Grad Sch Med, Dept Respirol, Chiba, Japan

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2022年 / 14卷

关键词：

EGFR; histologic transformations; lineage plasticity; non-small-cell lung cancer; small-cell lung cancer; SQUAMOUS-CELL CARCINOMA; TYROSINE KINASE INHIBITORS; ALK-REARRANGED ADENOCARCINOMA; NONSMALL CELL; ACQUIRED-RESISTANCE; PROSTATE-CANCER; NEUROENDOCRINE CARCINOMA; SOMATIC INACTIVATION; RETINOBLASTOMA GENE; GENOMIC ANALYSIS;

D O I：

10.1177/17588359221130503

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Histologic transformation (HT) is a major cause of drug resistance to therapy in patients with lung cancer. HTs to small-cell lung cancer (SCLC) have been reported frequently in patients with epidermal growth factor receptor (EGFR)-mutated lung cancer. Although HTs have an impact on the clinical outcomes in patients owing to a high refractoriness to treatments, there is limited data on the prevalence, causes, mechanisms, treatment efficacy, and future treatment strategies. In this review, we assess the literature regarding HTs comprehensively, including those describing EGFR-tyrosine kinase inhibitors, other molecular targeted drugs, and immune checkpoint inhibitors. Furthermore, we discuss the mechanisms of HTs and the lineage plasticity to SCLC and squamous cell carcinoma in lung cancer. In addition, we summarize the treatment efficacy and future perspectives of HTs in patients with lung cancer, and propose better management strategies for this group of patients.

引用

页数：18

共 138 条

[31] Comprehensive genomic characterization of squamous cell lung cancers [J].

Hammerman, Peter S. ;

Lawrence, Michael S. ;

Voet, Douglas ;

Jing, Rui ;

Cibulskis, Kristian ;

Sivachenko, Andrey ;

Stojanov, Petar ;

McKenna, Aaron ;

Lander, Eric S. ;

Gabriel, Stacey ;

Getz, Gad ;

Sougnez, Carrie ;

Imielinski, Marcin ;

Helman, Elena ;

Hernandez, Bryan ;

Pho, Nam H. ;

Meyerson, Matthew ;

Chu, Andy ;

Chun, Hye-Jung E. ;

Mungall, Andrew J. ;

Pleasance, Erin ;

Robertson, A. Gordon ;

Sipahimalani, Payal ;

Stoll, Dominik ;

Balasundaram, Miruna ;

Birol, Inanc ;

Butterfield, Yaron S. N. ;

Chuah, Eric ;

Coope, Robin J. N. ;

Corbett, Richard ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Anhe Carrie ;

Hirst, Martin ;

Holt, Robert A. ;

Lee, Darlene ;

Li, Haiyan I. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Karen ;

Nip, Ka Ming ;

Olshen, Adam ;

Schein, Jacqueline E. ;

Slobodan, Jared R. ;

Tam, Angela ;

Thiessen, Nina ;

Varhol, Richard ;

Zeng, Thomas ;

Zhao, Yongjun ;

Jones, Steven J. M. .

NATURE, 2012, 489 (7417) :519-525

[32] Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma [J].

Han, Xiangkun ;

Li, Fuming ;

Fang, Zhaoyuan ;

Gao, Yijun ;

Li, Fei ;

Fang, Rong ;

Yao, Shun ;

Sun, Yihua ;

Li, Li ;

Zhang, Wenjing ;

Ma, Huimin ;

Xiao, Qian ;

Ge, Gaoxiang ;

Fang, Jing ;

Wang, Hongda ;

Zhang, Lei ;

Wong, Kwok-Kin ;

Chen, Haiquan ;

Hou, Yingyong ;

Ji, Hongbin .

NATURE COMMUNICATIONS, 2014, 5

[33] Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer [J].

Hanna, N ;

Bunn, PA ;

Langer, C ;

Einhorn, L ;

Guthrie, T ;

Beck, T ;

Ansar, R ;

Ellis, P ;

Byrne, M ;

Morrison, M ;

Hariharan, S ;

Wang, B ;

Sandler, A .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2038-2043

[34] ABNORMALITIES IN STRUCTURE AND EXPRESSION OF THE HUMAN RETINOBLASTOMA GENE IN SCLC [J].

HARBOUR, JW ;

LAI, SL ;

WHANGPENG, J ;

GAZDAR, AF ;

MINNA, JD ;

KAYE, FJ .

SCIENCE, 1988, 241 (4863) :353-357

[35] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].

Horn, L. ;

Mansfield, A. S. ;

Szczesna, A. ;

Havel, L. ;

Krzakowski, M. ;

Hochmair, M. J. ;

Huemer, F. ;

Losonczy, G. ;

Johnson, M. L. ;

Nishio, M. ;

Reck, M. ;

Mok, T. ;

Lam, S. ;

Shames, D. S. ;

Liu, J. ;

Ding, B. ;

Lopez-Chavez, A. ;

Kabbinavar, F. ;

Lin, W. ;

Sandler, A. ;

Liu, S. V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229

[36] Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy [J].

Hsieh, Min-Shu ;

Lin, Mong-Wei ;

Lee, Yi-Hsuan .

LUNG CANCER, 2019, 137 :76-84

[37]

Huang J., 2022, JTO CLIN RES REP, V3

[38] Small cell transformation of non-small cell lung cancer under immunotherapy: Case series and literature review [J].

Imakita, Takuma ;

Fujita, Kohei ;

Kanai, Osamu ;

Okamura, Misato ;

Hashimoto, Masayuki ;

Nakatani, Koichi ;

Sawai, Satoru ;

Mio, Tadashi .

THORACIC CANCER, 2021, 12 (22) :3062-3067

[39]

Imakita T, 2017, RESPIR MED CASE REP, V21, P52, DOI 10.1016/j.rmcr.2017.03.019

[40] EFFECTS OF AN RB MUTATION IN THE MOUSE [J].

JACKS, T ;

FAZELI, A ;

SCHMITT, EM ;

BRONSON, RT ;

GOODELL, MA ;

WEINBERG, RA .

NATURE, 1992, 359 (6393) :295-300

← 1 2 3 4 5 6 7 8 9 10 →